Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea [0.03%]
索拉非尼和瑞戈非尼对晚期肝细胞癌的实际系统序贯疗法：韩国的多中心回顾性研究
Min Jin Lee,Sung Won Chang,Ji Hoon Kim et al.
Min Jin Lee et al.
Background/Aims Regorafenib has been approved as a second-line systemic therapy for hepatocellular carcinoma (HCC) patients after the phase III RESORCE trial. This study analyzed real-world data to assess the clinical effectiveness and safe...
Multicenter Study
Investigational new drugs. 2021 Feb;39(1):260-268. DOI:10.1007/s10637-020-00977-4 2021
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors [0.03%]
一项关于Cobimetinib (GDC-0973) 和 Ipatasertib (GDC-0068) 在局部晚期或转移性实体瘤患者中的安全性，药代动力学和药效学的Ib期开放标签剂量递增研究
Geoffrey I Shapiro,Patricia LoRusso,Daniel C Cho et al.
Geoffrey I Shapiro et al.
Background: This Phase Ib study explored combination dosing of the allosteric MEK1/2 inhibitor cobimetinib and the ATP-competitive pan-AKT inhibitor ipatasertib. ...
Novel Bacillus strains from the human gut exert anticancer effects on a broad range of malignancy types [0.03%]
来自人体肠道的新型棒状杆菌菌株对多种恶性肿瘤具有抗癌作用
Man-Fei Zhao,Gong-Da Liang,Yu-Jie Zhou et al.
Man-Fei Zhao et al.
Cancer is one of the leading causes of death worldwide, but effective therapies remain the topic of many research activities. Many recent studies have thus focused on particular gut microbiota due to their important roles in treating cancer...
Eli Gumnit,Aden C Feustel,Sandy Wong et al.
Eli Gumnit et al.
Major advances in cancer care often emerge from the development of novel targets. We randomly sampled 10% of cancer trials on clinicaltrials.gov with start dates 2013-2016 to determine the proportion of trials and research subjects directed...
Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report [0.03%]
尼沃单抗治疗肺腺癌诱发的抗转录中介因子1-γ抗体阳性皮肌炎1例报告
Megumu Osaki,Ryo Tachikawa,Junichiro Ohira et al.
Megumu Osaki et al.
Immune checkpoint inhibitors can induce immune-related adverse events (irAEs) in different organs. Dermatomyositis is a rare form of systemic irAE. Although dermatomyositis-specific antibodies, especially anti-transcriptional intermediary f...
Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent [0.03%]
一种新型且高效的EGFR抑制剂AL906的亚细胞分布及作用机制研究及其具有绿色荧光特性
Nahid Golabi,Anne-Laure Larroque,Lisa Peyrard et al.
Nahid Golabi et al.
To enhance the potency of EGFR inhibitors, we developed a novel strategy that seeks to conjugate EGFR to a bioactive moiety leading to a molecule termed "combi-molecule". In order to mimic the penetration of this type of molecules, based up...
Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib [0.03%]
蛋白酶体抑制剂万丹替尼引起的急性肾小管间质性肾炎
Melissa Pilco Teran,Ana Merino Ribas,Nadia Martin Alemany et al.
Melissa Pilco Teran et al.
Few cases of immunoallergic tubulointerstitial nephritis associated with tyrosine kinase inhibitors have been described. We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment o...
Jarosław Ciekot,Mateusz Psurski,Katarzyna Jurec et al.
Jarosław Ciekot et al.
Clinical and experimental cancer therapy is multifaceted; one such facet is the use of drug carriers. Drug carriers are various nano- and macromolecules, e.g., oligosaccharides, proteins, and liposomes. The present study aimed to verify the...
Johannes J M Rood,Amer Jamalpoor,Stephanie van Hoppe et al.
Johannes J M Rood et al.
Ibrutinib is a first-in-class Bruton's kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed. Subsequently, metabolism of the conjugates and finally ...
Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer [0.03%]
卡铂联合丝裂霉素C治疗复发性BRCA1相关卵巢癌的系统疗法
Tatyana V Gorodnova,Anna P Sokolenko,Sergey V Kondratiev et al.
Tatyana V Gorodnova et al.
Background Previous studies on neoadjuvant therapy for BRCA1-driven ovarian cancer (OC) demonstrated higher efficacy of mitomycin C plus cisplatin combination as compared to standard drug schemes. These data call for evaluation of the utili...